New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Heatwurx Inc. (PCSA) EV/Sales

Alert me on EV/Sales

As of 19 November 2026, Heatwurx Inc. (PCSA) trades at a EV/Sales of −1,326×. Over the past ten years it has ranged from −1,334× (October 2026) to 2,590× (March 2015); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.1× and below the Healthcare sector median of 3.3×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2015 41.2× —

Quarterly newest first

Period EV/Sales Change
Mar 2016 26.2× (36.37%)
Dec 2015 41.2× 3.62%
Sep 2015 39.8× (48.03%)
Mar 2015 76.6× —

Against its own ten years

Low −1,334× High 2,590×
Ten-year median 191×
Current reading's percentile 0

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PCSA